1Keimyung University Graduate School, Daegu, Republic of Korea
2College of Nursing, Keimyung University, Daegu, Republic of Korea
© 2023 Korea Disease Control and Prevention Agency.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ethics Approval
This study was approved by the Institutional Review Board of Keimyung University (IRB No: 40525-201610-HR-114-01) and performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained for the publication of this study and accompanying images.
Conflicts of Interest
The authors have no conflicts of interest to declare.
Funding
None.
Availability of Data
The datasets are not publicly available but are available from the corresponding author upon reasonable request.
Authors’ Contributions
Conceptualization: all authors; Data curation: all authors; Formal analysis: all authors; Funding acquisition: all authors; Investigation: HL; Methodology: GB, EL; Project administration: all authors; Resources: all authors; Software: all authors; Supervision: all authors; Validation: all authors; Visualization: all authors; Writing–original draft: all authors; Writing–review & editing: all authors. All authors read and approved the final manuscript.
Subject | Preliminary investigation | Intervention | Post-investigation 1 | Post-investigation 2 |
---|---|---|---|---|
Experimental group | Ye1 | Xe | Ye2 | Ye3 |
Control group | Yc1 | Yc2 | Yc3 |
AVF, arteriovenous fistula; Xe, AVF stenosis prevention program (AVF upper extremity strength exercise, health education on phosphorus-restricted diet and AVF management, health counseling, and text messages); Ye1, Yc1, investigation of general and disease-related characteristics, upper extremity muscle strength measurement, blood flow velocity measurement, serum calcium and phosphorus measurement, and self-efficacy measurement; Ye2, Ye3, Yc2, and Yc3, measurement of upper extremity muscle strength, blood flow rate, serum calcium and phosphorus levels, and self-efficacy.
Characteristic | Experimental group (n=25) | Control group (n=25) | χ2/Fishera) | p |
---|---|---|---|---|
Sex | ||||
Male | 14 (56.0) | 10 (40.0) | 1.28 | 0.258 |
Female | 11 (44.0) | 15 (60.0) | ||
Age (y) | ||||
<54 | 12 (48.0) | 11 (44.0) | 0.08 | 0.777 |
≥54 | 13 (52.0) | 14 (56.0) | ||
Marital status | ||||
Married | 18 (72.0) | 14 (56.0) | 1.61a) | 0.517 |
Not married | 4 (16.0) | 5 (20.0) | ||
Otherb) | 3 (12.0) | 6 (24.0) | ||
Family | ||||
Yes | 22 (88.0) | 21 (84.0) | 0.17a) | 0.500 |
No | 3 (12.0) | 4 (16.0) | ||
Education | ||||
Less than middle school | 6 (24.0) | 7 (28.0) | 0.14 | 0.931 |
High school | 11 (44.0) | 11 (44.0) | ||
College or higher | 8 (32.0) | 7 (28.0) | ||
Job status | ||||
Employed | 10 (40.0) | 6 (24.0) | 1.47 | 0.225 |
Not employed | 15 (60.0) | 19 (76.0) | ||
Economic status | ||||
Medium or higher | 15 (60.0) | 12 (48.0) | 0.73 | 0.395 |
Low | 10 (40.0) | 13 (52.0) | ||
Dialysis period (y) | ||||
<5 | 14 (56.0) | 10 (40.0) | 1.28 | 0.258 |
≥5 | 11 (44.0) | 15 (60.0) | ||
Causative disease | ||||
Diabetes | 6 (24.0) | 3 (12.0) | 1.37a) | 0.821 |
Hypertension | 10 (40.0) | 12 (48.0) | ||
Chronic glomerulonephritis | 7 (28.0) | 8 (32.0) | ||
Otherc) | 2 (8.0) | 2 (8.0) | ||
Body weight (kg) | ||||
<60 | 12 (48.0) | 12 (48.0) | 0.00 | 1.000 |
60−69 | 8 (32.0) | 8 (32.0) | ||
≥70 | 5 (20.0) | 5 (20.0) | ||
Weight gain after dialysis (kg) | ||||
1−2 | 7 (28.0) | 7 (28.0) | 1.80 | 0.407 |
2−3 | 8 (32.0) | 12 (48.0) | ||
>3 | 10 (40.0) | 6 (24.0) | ||
Heparin usage (U) | ||||
≤600 | 23 (92.0) | 19 (76.0) | 2.38a) | 0.123 |
≥800 | 2 (8.0) | 6 (24.0) | ||
Maturity period (wk) | ||||
≤5 | 7 (28.0) | 7 (28.0) | 0.00 | 1.000 |
≥6 | 18 (72.0) | 18 (72.0) | ||
Occlusion experience | ||||
None | 15 (60.0) | 12 (48.0) | 5.33a) | 0.083 |
1 or 2 | 9 (36.0) | 6 (24.0) | ||
≥3 | 1 (4.0) | 7 (28.0) | ||
Location of AVF | ||||
Left wrist | 5 (20.0) | 3 (12.0) | 5.34a) | 0.394 |
Left forearm | 11 (44.0) | 10 (40.0) | ||
Left upper arm | 6 (24.0) | 3 (12.0) | ||
Right wrist | 0 (0) | 3 (12.0) | ||
Right forearm | 1 (4.0) | 3 (12.0) | ||
Right upper arm | 2 (8.0) | 3 (12.0) | ||
Duration of AVF use (y) | ||||
<4 | 14 (56.0) | 9 (36.0) | 2.01 | 0.156 |
≥4 | 11 (44.0) | 16 (64.0) | ||
Smoking status | ||||
Non-smoker | 23 (92.0) | 21 (84.0) | 0.76a) | 0.334 |
Smoker | 2 (8.0) | 4 (16.0) | ||
No. of medications | ||||
<7 | 13 (52.0) | 12 (48.0) | 0.08 | 0.777 |
≥8 | 12 (48.0) | 13 (52.0) |